Download
18_Dubrall_be4920_als06042_englisch.pdf 772,57KB
WeightNameValue
1000 Titel
  • Descriptive analysis of adverse drug reaction reports for hypersensitivity reactions stratified in relation to different beta-lactam antibiotics
1000 Autor/in
  1. Dubrall, Diana |
  2. Schulz, Maike |
  3. Schmid, Matthias |
  4. Sachs, Bernhardt |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-02-03
1000 Erschienen in
1000 Quellenangabe
  • 6(1):42-60
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.5414/ALX02189E |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822522/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • β-lactam antibiotics (BLA) are commonly reported to induce hypersensitivity reactions. However, β-lactam antibiotic-stratified analyses are rare. In the presented study, β-lactam antibiotic associated hypersensitivity reactions were analyzed in the European adverse drug reaction (ADR) database. 923, 38, 222, and 99 hypersensitivity reports for penicillins and first-, second- and third-generation cephalosporins were reported. Differences with regard to demographical parameters, seriousness and types of hypersensitivity reactions, as well as in the number of hypersensitivity reports per outpatient prescriptions were observed between the different β-lactam antibiotics. The number of ADR reports classified as serious was higher for all generations of cephalosporins compared to penicillins. Additionally, anaphylactic reactions were more often reported for first- and second-generation cephalosporins compared to third-generation cephalosporins and penicillins, while bullous reactions were more often reported for first- and third-generation cephalo­sporins as opposed to second-generation cephalosporins and penicillins. The observed differences may be caused by differences between β-lactam antibiotics and their routes of administration (oral, intravenous), the patient populations, or the reporting of ADRs. Due to the methodological limitations of ADR database analysis, no conclusions can be drawn whether and to what extent the aforementioned factors influenced our results.
1000 Sacherschließung
lokal anaphylaxis
lokal side effects
lokal adverse drug reaction database analysis
lokal beta- lactam antibiotics
lokal allergy
lokal adverse drug reactions
lokal cephalosporin
lokal cutaneous reactions
lokal hypersensitivity reaction
lokal penicillin
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RHVicmFsbCwgRGlhbmE=|https://frl.publisso.de/adhoc/uri/U2NodWx6LCBNYWlrZQ==|https://frl.publisso.de/adhoc/uri/U2NobWlkLCBNYXR0aGlhcw==|https://frl.publisso.de/adhoc/uri/U2FjaHMsIEJlcm5oYXJkdCAg
1000 Label
1000 Förderer
  1. Bundesinstitut für Arzneimittel und Medizinprodukte |
  2. Universitätsklinikum Bonn |
1000 Fördernummer
  1. -
  2. V-16703/68502/2016-2020
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
  1. Dustri Open Access Statement Allergologie Select
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Bundesinstitut für Arzneimittel und Medizinprodukte |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Bonn |
    1000 Förderprogramm -
    1000 Fördernummer V-16703/68502/2016-2020
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6432804.rdf
1000 Erstellt am 2022-04-05T11:00:47.590+0200
1000 Erstellt von 280
1000 beschreibt frl:6432804
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Fri Apr 08 07:26:21 CEST 2022
1000 Objekt bearb. Fri Apr 08 07:26:03 CEST 2022
1000 Vgl. frl:6432804
1000 Oai Id
  1. oai:frl.publisso.de:frl:6432804 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source